Imunoexpressão da proteína hMSH2 em leucoplasia bucal
Imunodetection of protein hMSH2 in the oral leukoplakia
Pontes, F.S.C.; Pontes, H.A.R.; Aguiar, M.C.F.; Silveira Jr., J.B.; Silva, T.S.P.; Mesquita, R.A.
Rev. odontol. UNESP, vol.35, n1, p.107-112, 2006
Resumo
A leucoplasia é a principal alteração potencialmente maligna da boca. Embora o fumo, intensificado pelo consumo de álcool, seja o agente etiológico mais importante para a leucoplasia bucal, estudos complementares são importantes para o entendimento da patogenia da transformação maligna dessa alteração. Realizou-se este estudo com o objetivo de analisar a imunoexpressão da proteína de reparo do DNA hMSH2 em amostras de leucoplasia bucal com aspectos morfo-citológicos de hiperceratose e atipia epitelial (discreta, moderada e acentuada), assim como no epitélio de mucosa bucal normal. Os resultados não mostraram diferenças estatisticamente significantes quando as imunomarcações das graduações histológicas das leucoplasias bucais foram avaliadas entre si, assim como não houve diferenças estatisticamente significantes com a mucosa bucal normal. Esses resultados avaliados em conjunto sugerem que a proteína hMSH2 não está relacionada aos variados graus de atipia epitelial encontrados na histopatologia da leucoplasia bucal, sugerindo que a proteína hMSH2 não participa do processo de transformação maligna da leucoplasia bucal para carcinoma epidermóide. Porém, mais estudos são necessários para confirmar esses resultados.
Palavras-chave
Carcinogênese, imuno-histoquímica, leucoplasia bucal, hMSH2
Abstract
The oral leukoplakia is the main oral precancerous lesion. Even though the fume, potentiated by alcohol drinks, is the most important etiologic agent of both oral leukoplakia and squamous cells carcinoma, other complementary studies are necessary for the pathogenesis understanding of the malignant transformation of this lesion. Therefore, the purpose of this study was to describe and to analyze the repair protein of DNA hMSH2 protein immunoexpression in oral leukoplakia samples with different degrees of epithelial dysplasia (mild, moderated and severe), as well as in normal oral mucosa epithelium. The results did not show significant statistic differences when the oral leukoplakia with different degrees of epithelial dysplasia were compared with each other, neither there was a statistical significant difference among the oral leukoplakia samples and the normal oral mucosa. These results suggest that the hMSH2 protein does not partake on oral leukoplakia development into oral squamous cells carcinoma.
Keywords
Carcinogenesis, immunohistochemical, oral leucoplakia
References
1. � � � � � � � � � � � � Waal IVD, Schepman KP, Meiji EH, Smeele LE. Oral leukoplakia: a clinicopathological review. Oral Oncol. 1997; 33B:291-301.
2. Waldron CA, Shafer WG. Leukoplakia revisited: a clinicopathologic study 3256 oral leucoplakias. Cancer. 1975, 36:1386-92.
3. Banoczy J. Follow-up studies in oral leukoplakia. J Maxillofac Surg. 1977; 5 (56):69-75.
4. Cheng LH, Hudson J. Ultrastructural changes in malignant tranformation of oral mucosa. Br J Oral Maxillofac Surg. 2002; 40:207-12.
5. Klein-Szanto, AJP, Banoczy J, Schroeder HE. Metaplastic conversion of the differentiation pattern in oral epithelia affected by leukoplakia simplex. A stereologic study. Pathol Eur.1976; 11:189-210.
6. Lind PO. Malignant transformation in oral leukoplakia. Scand J Dent Res. 1987; 95: 449-55.
7. Scheifele C, Reichart PA. Is there a natural limit of the transformation rate of oral leukoplakia? Oral Oncol. 2003; 39: 470-5.
8. Okazaki Y, Tanaka Y, Tonogi M, Yamane G. Investigation of environmental factors for diagnosing malignant potential in oral epithelial dysplasia. Oral Oncol. 2002; 38: 562-73.
9. Oliver RJ, Macdonald DG, Felix DH. Aspects of cell proliferation in oral ephitelial dysplastic lesions. J Oral Pathol Med. 2000; 29: 49-55.
10. Sudbo J, Reith A. When is an oral leukoplakia premalignant? Oral Oncol. 2002; 38: 813-4.
11. Jefferies S, Foulkes WD. Genetic Mechanisms in squamous cell carcinoma of the head and neck. Oral Oncol. 2001; 37: 115-26.
12. Lippman S, Hong WK. Molecular Markers of the risk of oral cancer. N Engl J Med. 2001; 34: 1323-6.
13. Liu SC, Klein-Szanto AJP. Markers of proliferation in normal and leukoplakic oral epithelia. Oral Oncol. 2000; 36:145-51.
14. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/ pro-apoptotic dual-role proteins in five major DNA repair pathways: fall-safe protection against carcinogenesis. Mutat Res. 2002; 511:145-78.
15. Nunn J, Naginis S, Risk JM, Prime W, Maloney P, Liloglou T, et al. Allellic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3, in squamous cell carcinoma of the head and neck. Oral Oncol. 2003: 39:115-29.
16. Habraken Y, Sung P, Prakash L, Prakash S. Enhancement of MSH2-MSH3-mediated mismatch recognition by the yeast MLH1-PMS1 complex. Curr Biol. 1997; 7: 790-7.
17. Marti MT, Kunz C, Fleck O. DNA Mismatch Repair and Mutation Avoidance Pathways. J Cell Physiol. 2002;191 (9): 28-41.
18. Drotschmann K, Shcherbakova VP, Kunkel AT. �Mutator phenotype due to loss of heterozygosity in diploid yeast strains with mutations in MSH2 and MLH1. Toxicol Lett. 2000;112 (113): 239-44.
19. Perrin J, Parriaux D, Noguchi T, Giovannini MH, Giovannini M, Delpero JR et al. MSH2 and MLH1 immunodetection and the prognosis of colon cancer. Int J Oncol. 2001:19: 891-5.
20. Pyatt RE, Nakagawa H, Hampel H, Sedra M, Fuchik MB, Comeras I. Identification of a deletion in the mismatch repair gene, MSH2, using mouse-human cell hybrids monosomal for chromosome 2. Clin Genet. 2003; 63: 215-8.
21. Uehara H, Miyamoto M, Kato K, Cho Y, Kurokawa T, Murakami S, et al. Deficiency of hMLH1 and hMSH2 Expression Is a Poor Prognostic Factor in Esophageal Squamous Cell Carcinoma. J Surg Oncol. 2005; 92: 109-15.
22. Paula AMB, Gomez RS. Immunolocalization of p53, glutathione S-transferase and CD57 antigens in oral leukoplakia. Anticancer Res. 2001; 21:379-85.
23. Ayres M, Ayres DL, Santos AS. Aplicações estatísticas nas áreas das ciências biológicas e médicas. IOEPA. 2003; 22:227-64.
24. Vora HV, Shah NG, Patel DD, Trivetdi TI, Choksi TJ. BRCA1 Expression in leukoplakia and carcinoma of the tongue. J Surg Oncol. 2003; 83: 232-40.
25. Leach FS, Polyak K, Burrellin M, Jonhson KA, Hill D, Dunlop MG, et al. Expression of the human mismatch repair gene hMSH2 in normal and neoplasic tissues. Cancer Res. 1996; 56: 235-40.
26. Kariola R, Otway R, Lonnqvist KE, Raevaara TE, Macrae F, Vos YJ, et al. Two mismatch repair gene mutations found in colon cancer patient- which one is pathogenic? Hum Genet. 2002; 112: 105-9.
27. Mu David, Mihray T, Duckett DR, Drummond JT, Modrich P, Sancar A. Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. Mol Cell Biol. 1997; 17: 760-9.
28. O’Brien V, Brown R. Signalling cell cycle arrest and cell death throught the MMR system. Carcinogenesis. 2005, 6: 1-36.
29. Chung CD, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003; 7: 560-70.
30. Bernstein C, Bernestein H, Payne CM, Garewal H. DNA repair/ pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. � � � � � Mutat Res. 2002; 511: 145-78.
31. Marti TM, Kunz C, Fleck O. DNA mismatch repair and mutation avoidance pathways. J Cell Physiol. 2002; 191: 28-41.
32. � � � � � � � � � � Pontes HAR, Aguiar MCF, Mesquita RA, Pontes FSC, Silveira Júnior JB. Imunoexpressão da proteína de reparo hMSH2 em queilite actínica e mucosa labial normal. Rev Bras Cancerol. 2005; 51(1): 23-30.
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email